10 research outputs found

    Aberrant overexpression of an epithelial marker, 14-3-3σ, in a subset of hematological malignancies

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>14-3-3σ is a p53-mediated cell-cycle inhibitor in epithelial cells. The expression of 14-3-3σ is frequently altered in cancers of epithelial origin associated with altered DNA methylation. Since its involvement in a non-epithelial tumor is unknown, we examined 14-3-3σ expression in patients with haematological malignancies.</p> <p>Methods</p> <p>We analyzed 41 hematopoietic cell lines and 129 patients with a variety of hematological malignancies for 14-3-3σ expression with real-time RT-PCR. We also examined protein levels by Western blot analysis and DNA methylation status of the 14-3-3σ gene by methylation-specific PCR analysis of bisulfite-treated DNA. In addition, mutations of p53 gene were identified by RT-PCR-SSCP analysis and the expression levels of 14-3-3σ were compared with those of other cell-cycle inhibitor genes, CDKN2A and ARF.</p> <p>Results</p> <p>The expression levels of 14-3-3σ mRNA in almost all cell lines were low and comparable to those in normal hematopoietic cells except for 2 B-cell lines. On the contrary, 14-3-3σ mRNA was aberrantly overexpressed frequently in mature lymphoid malignancies (30 of 93, 32.3%) and rarely in acute leukemia (3 of 35, 8.6%). 14-3-3σ protein was readily detectable and roughly reflected the mRNA level. In contrast to epithelial tumors, methylation status of the 14-3-3σ gene was not associated with expression in hematological malignancies. Mutations of p53 were identified in 12 patients and associated with lower expression of 14-3-3σ. The expression levels of 14-3-3σ, CDKN2A and ARF were not correlated with but rather reciprocal to one another, suggesting that simultaneous overexpression of any two of them is incompatible with tumor growth.</p> <p>Conclusion</p> <p>14-3-3σ, an epithelial cell marker, was overexpressed significantly in a subset of mature lymphoid malignancies. This is the first report of aberrant 14-3-3σ expression in non-epithelial tumors <it>in vivo</it>. Since the significance of 14-3-3σ overexpression is unknown even in epithelial tumors such as pancreatic cancers, further analysis of regulation and function of the 14-3-3σ gene in non-epithelial as well as epithelial tumors is warranted.</p

    Activation of genes inducing cell-cycle arrest and of increased DNA repair in the hearts of rats with early streptozotocin-induced diabetes mellitus.

    No full text
    BACKGROUND: Oxidative stress was proposed as a critical factor in diabetic complications. The etiology of cell degeneration in diabetes mellitus (DM)-induced cardiomyopathy is unclear. The transition between apoptotic degeneration and cell proliferation under stress conditions is regulated at cell-cycle checkpoints. This study was aimed at elucidating the role of a potent cellular stress-response system of the p53-dependent checkpoint genes, i.e. P21WAF1/CIP1 and 14-3-3 sigma, in the heart in diabetes. MATERIAL/METHODS: Target gene expression levels were analyzed ex vivo in cardiomyocytes of streptozotocin-induced rats by Western blots and two-dimensional immunoblots. The levels of DNA damage/repair in diabetic cardiomyocytes were evaluated by "comet assay" and compared with a control group. RESULTS: Whereas no detectable expression of 14-3-3 sigma and only traces of both p53 and p21WAF1/CIP1 were found in cardiomyocytes of the controls, high expression rates of all three genes were observed in the DM group. Individual levels of DNA breakage were significantly lower in diabetic than in non-diabetic cardiomyocytes. CONCLUSIONS: We propose a dual role for cell-cycle regulation under diabetic conditions: the expressions of both p21WAF1/CIP1 and 14-3-3 sigma genes, activated via p53 function, trigger cell-cycle arrest and DNA repair, preventing replication of mutated DNA and increasing stress resistance of heart tissue at least in early diabetes. However, the double cell-cycle arrest ultimately inhibits the replication of cells, which consequently accumulate in the G1 and G2 phases; this could lead to retarded proliferative activity and tissue degeneration in diabetic myocardium in later diabetes

    The primary vascular dysregulation syndrome: implications for eye diseases

    Get PDF
    Vascular dysregulation refers to the regulation of blood flow that is not adapted to the needs of the respective tissue. We distinguish primary vascular dysregulation (PVD, formerly called vasospastic syndrome) and secondary vascular dysregulation (SVD). Subjects with PVD tend to have cold extremities, low blood pressure, reduced feeling of thirst, altered drug sensitivity, increased pain sensitivity, prolonged sleep onset time, altered gene expression in the lymphocytes, signs of oxidative stress, slightly increased endothelin-1 plasma level, low body mass index and often diffuse and fluctuating visual field defects. Coldness, emotional or mechanical stress and starving can provoke symptoms. Virtually all organs, particularly the eye, can be involved. In subjects with PVD, retinal vessels are stiffer and more irregular, and both neurovascular coupling and autoregulation capacity are reduced while retinal venous pressure is often increased. Subjects with PVD have increased risk for normal-tension glaucoma, optic nerve compartment syndrome, central serous choroidopathy, Susac syndrome, retinal artery and vein occlusions and anterior ischaemic neuropathy without atherosclerosis. Further characteristics are their weaker blood-brain and blood-retinal barriers and the higher prevalence of optic disc haemorrhages and activated astrocytes. Subjects with PVD tend to suffer more often from tinnitus, muscle cramps, migraine with aura and silent myocardial ischaemic and are at greater risk for altitude sickness. While the main cause of vascular dysregulation is vascular endotheliopathy, dysfunction of the autonomic nervous system is also involved. In contrast, SVD occurs in the context of other diseases such as multiple sclerosis, retrobulbar neuritis, rheumatoid arthritis, fibromyalgia and giant cell arteritis. Taking into consideration the high prevalence of PVD in the population and potentially linked pathologies, in the current article, the authors provide recommendations on how to effectively promote the field in order to create innovative diagnostic tools to predict the pathology and develop more efficient treatment approaches tailored to the person

    The discovery of the Flammer syndrome: a historical and personal perspective

    No full text
    corecore